A share price of Adaptive Biotechnologies Corp [ADPT] is currently trading at $20.46, up 9.94%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ADPT shares have gain 49.23% over the last week, with a monthly amount glided 18.82%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Adaptive Biotechnologies Corp [NASDAQ: ADPT] stock has seen the most recent analyst activity on September 30, 2025, when Guggenheim initiated its Buy rating and assigned the stock a price target of $20. Previously, Craig Hallum started tracking the stock with Buy rating on June 18, 2025, and set its price target to $15. On March 21, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $9 on the stock. Scotiabank initiated its recommendation with a Sector Outperform and recommended $15 as its price target on January 05, 2023. Piper Sandler upgraded its rating to Overweight for this stock on December 21, 2022, and upped its price target to $14. In a note dated August 25, 2022, Credit Suisse initiated an Underperform rating and provided a target price of $8 on this stock.
Adaptive Biotechnologies Corp experienced fluctuations in its stock price throughout the past year between $4.29 and $18.98. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Adaptive Biotechnologies Corp [NASDAQ: ADPT] shares were valued at $20.46 at the most recent close of the market. An investor can expect a potential drop of -2.25% based on the average ADPT price forecast.
Analyzing the ADPT fundamentals
Trailing Twelve Months sales for Adaptive Biotechnologies Corp [NASDAQ:ADPT] were 252.75M which represents 102.38% growth. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at -0.59%, Pretax Profit Margin comes in at -0.59%, and Net Profit Margin reading is -0.59%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.61 and Total Capital is -0.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.47.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.02 points at the first support level, and at 17.59 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.27, and for the 2nd resistance point, it is at 22.09.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Adaptive Biotechnologies Corp [NASDAQ:ADPT] is 3.38. As well, the Quick Ratio is 3.26, while the Cash Ratio is 0.47. Considering the valuation of this stock, the price to sales ratio is 12.36, the price to book ratio is 15.27.
Transactions by insiders
Recent insider trading involved BENZENO SHARON, Chief Commercial Ofc Imm Med, that happened on Nov 21 ’25 when 0.31 million shares were sold. Chief Commercial Ofc Imm Med, BENZENO SHARON completed a deal on Nov 20 ’25 to sell 0.3 million shares. Meanwhile, Officer SHARON BENZENO bought 0.31 million shares on Nov 21 ’25.
